Ecabet

Summary

Ecabet (CHEMBL2104585) is a phase-3 clinical-stage small molecule; indicated across 1 condition including dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 380.5 Da · C20H28O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104585
Name	Ecabet
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65781
Molecular formula	C20H28O5S
Molecular weight	380.5
InChIKey	IWCWQNVIUXZOMJ-MISYRCLQSA-N

SMILES: CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)S(=O)(=O)O

IUPAC name: (1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-6-sulfo-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid

Also known as: Ecabet, SID144206316, ECABET, ecabet, C0088636

Parent form; salt/anhydrous children: CHEMBL3186947, CHEMBL3343738, CHEMBL4303208

Patent coverage: 220 distinct patent families (865 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 863 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Kappa-type opioid receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	2	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01308177	PHASE4	UNKNOWN	Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection
NCT00198536	PHASE2/PHASE3	COMPLETED	Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT00370747	PHASE2	COMPLETED	Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).